Our Best View Yet of Interstellar Comet 3I/ATLAS
The Gemini North telescope on Maunakea, Hawaii, recently snapped a close-up of 3I/ATLAS, the third interstellar object ever discovered. The telescope's highly sensitive Multi-Object Spectrograph captured the comet's compact coma—a cloud of gas and dust surrounding its icy nucleus—in striking detail. 3I/ATLAS is inbound to the inner solar system, and as it approaches the Sun and heats up, its coma will expand and make the comet appear brighter. Observing this uptick in activity, known as cometary outgassing, will allow astronomers to gain more insight into the composition of 3I/ATLAS. Understanding what this interstellar comet is made of will offer a glimpse of the conditions and processes that shaped the distant star system from which it came.
'The sensitivity and scheduling agility of the International Gemini Observatory has provided critical early characterization of this interstellar wanderer,' Martin Still, NSF program director for the International Gemini Observatory, said in a statement. 'We look forward to a bounty of new data and insights as this object warms itself on sunlight before continuing its cold, dark journey between the stars.'
The International Astronomical Union's Minor Planet Center confirmed that this comet came from outside our solar system on July 2. Since then, astronomers have been racing to gather as much data on it as possible. Preliminary findings suggest 3I/ATLAS is the oldest comet ever found, roughly 2 billion years older than our solar system. What's more, it appears to have come from an underexplored region of the Milky Way's galactic disk. This is the disk-like component of our galaxy containing stars, gas, and dust that rotates in a circular coplanar motion around the center of the galaxy. Based on its trajectory, 3I/ATLAS likely came from the thick part of the disk, which contains roughly 10% of the stellar mass of the Milky Way. Stars located in the thick disk are generally much older than those located in the galaxy's thin disk.
This comet is older, larger, and faster than the two interstellar objects that came before it: 'Oumuamua and Comet 2I/Borisov. One recent study, which has yet to undergo peer review, found that 3I/ATLAS has a hyperbolic velocity of about 37 miles per second (60 kilometers per second). That's roughly twice the speed of both 'Oumuamua and Borisov. The researchers also estimated the newly discovered comet to be up to 6 miles (10 kilometers) wide, which would make it 100 times wider than 'Oumuamua and 10 times wider than Borisov. If 3I/ATLAS truly is that big, this would imply that galaxies are far more efficient at making these kinds of objects than scientists thought. The study authors note, however, that estimations of this comet's size will likely shrink as astronomers gather more observations.
The Gemini Observatory and many others across the globe will continue using a wide variety of telescopes to observe 3I/ATLAS as it rockets toward the Sun. The comet should make its closest approach to our home star on October 29 and its closest approach to Earth on October 30. It will keep a safe distance from our planet, but the flyby will still allow astronomers to gather more detailed observations of this comet before it leaves our solar system for good.
Such studies could begin to unravel the many mysteries of 3I/ATLAS, as its characteristics remain largely unknown. Still, it's already becoming clear that this interstellar comet is totally different from any we've seen before, offering brand new insights into galactic processes beyond our solar system.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Stunning Grand Canyon Fossils Reveal Evolution's Weird Experiments
A stunning new fossil find from the Grand Canyon fills in some blanks from a time when evolution began experimenting with weird new forms. About half a billion years ago, life on Earth really started cooking in an event we now call the Cambrian explosion. The fossil record from that time reveals a spike in bizarre, complex creatures appearing within a relatively short amount of time, laying the roots for most of the major animal groups that exist today. Frustratingly, fossils from later in the Cambrian period are rarer, so we don't have a clear picture of evolution's experimental second album. But a newly discovered batch of extremely well-preserved fossils could patch up that gap. These are about 505 million years old – 3 million years younger than the Burgess Shale, the layer in which fossils from the Cambrian explosion appear. Related: A team led by researchers at the University of Cambridge found more than 1,500 small, carbonaceous fossils in samples from the Bright Angel Formation (BAF) of the Grand Canyon, which was once a shallow marine environment. The vast majority of the fossils are priapulid worms, along with a couple hundred crustaceans and a few mollusks. Although ecological resources were plentiful at the time, competition was also on the rise, rewarding species that exploited new niches. Analysis of these fossils revealed a variety of adaptations to do just that. A worm species called Kraytdraco spectatus, for example, was found to be covered in teeth sporting elaborate filaments, which varied in shape and length based on where they were on the body. The researchers suggest that they used their tougher teeth to scrape and rake surfaces, kicking up food particles that they could then filter out of the water using the longer filaments. Crustacean fossils featured signs of suspension feeding by way of tiny hairs that pushed food particles towards the mouth to be ground up by molar-like structures. The mollusks, meanwhile, sported rows of shovel-shaped teeth that could have been dragged front-to-back to scrape algae or microbes from surfaces. The Cambrian explosion gets plenty of attention because it's so well-represented in the fossil record, but that was just the beginning. The newly described fossils, with their exceptional level of preserved detail, provide a fascinating glimpse into the time soon after that, when complex life was established and comfortable, and had the stability to start innovating with new forms. And we should be glad it did: most of the major groups (or phyla) of animals got their start during the Cambrian. That includes arthropoda, encompassing all insects, arachnids, and crustaceans. And there's chordata, which includes us and the rest of our backbone-bearing brethren. The competitive period of the late Cambrian could have cemented the strategies that helped animals stay successful half a billion years later. "If the Cambrian Explosion laid the foundations of modern metazoan adaptive solutions, it is the scaling up of their competitive interactions that may have enforced directional, long-term trends of functional innovation in the Phanerozoic biosphere," the researchers write. The study was published in the journal Science Advances. Related News Neither Scales Nor Feathers: Bizarre Appendage Discovered on Reptile Fossil America's Largest Crater Has Surprise Link to Grand Canyon, Study Finds 500-Million-Year-Old Fossil Suggests Ocean Origin For Spiders Solve the daily Crossword
Geek Tyrant
an hour ago
- Geek Tyrant
Review: ALIEN: EARTH Episode 1 Delivers Pure Horror, Action, and Chaos; It Was Awesome! — GeekTyrant
I just got out of Hall H at Comic-Con after watching the first episode of Alien: Earth , and howly crap… this show absolutely lived up to the hype. It's awesome! This is a series I've been very excited about and the first epsiode didn't disappoint. It perfectly captures the DNA of Alien and Aliens while launching us into a bold, unsettling new chapter of the franchise. From the moment it started, the vibe had me hooked. Alien: Earth doesn't waste time easing you in, it throws you straight into a world that feels both familiar and terrifyingly unpredictable. The tone is pure dread layered with moments of explosive action and intense chaos. It's classic Alien horror mixed with heart-pounding action sequences. If I had to sum up the episode in one word, it would be unsettling. What really grabbed me was the story direction. Beneath the carnage and tension, there's a dark corporate angle that digs deep into power and greed… how far people will go to dominate, even if it means sacrificing humanity itself. This isn't just a horrific survival story, it's a sharp commentary on control and corruption in a world facing unimaginable threats. Add in the fascinating concept of transferring a human mind into a Synthetic body, and you've got a narrative that's as disturbing as it is compelling. Hardcore fans are going to lose their minds over this and just the first episode was filled with little things that you'll notice from the other films in the franchise. They're subtle but unmistakable, nods to the original films that feel like a reward for longtime devotees without beating you over the head with nostalgia. Then there's the score, which is chilling, pulsing with tension, and at times eerily beautiful. It amplifies the atmosphere in a way that feels absolutely right for this universe. It also takes cues from the music of Alien and Aliens . With a rumored budget that could exceed FX's Shōgun , which clocked in at $250 million, Alien: Earth might be one of the most expensive shows the network has ever produced, and it shows. Everything from the visual effects to the creature design and story screams high quality. The story kicks off when a specimen collection ship crash-lands on Earth, pulling Sydney Chandler's character and a squad of tactical soldiers into a nightmare that threatens the planet. If the rest of the series keeps this level of intensity, we're looking at something truly special. I can't wait to see where this goes.
Yahoo
an hour ago
- Yahoo
Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia
Initial results demonstrate numerical improvement of cognitive and functional measures with inidascamine across both active treatment arms compared to placebo, but did not meet statistical significance on the primary endpoint Inidascamine continues to exhibit a favorable safety and tolerability profile Full data set, including secondary endpoints and subgroup analyses will be forthcoming SOUTH SAN FRANCISCO, July 25, 2025 (GLOBE NEWSWIRE) -- Recognify Life Sciences, a clinical-stage biotech company focused on developing treatments for cognitive impairment, today announced that its randomized, double-blind, placebo-controlled Phase 2b clinical trial evaluating inidascamine (formerly RL-007) in patients with cognitive impairment associated with schizophrenia (CIAS) did not meet its primary endpoint. While the study did not achieve statistical significance on its primary endpoint of improvement on the Measurement and Treatment Research to Improve Cognition in Schizophrenia Consensus Cognitive Battery (MCCB) neurocognitive composite score at Week 6, inidascamine demonstrated a modest but consistent numerical improvement across the overall MCCB neurocognitive composite and multiple individual subdomains, including Symbol Coding, Speed of Processing and Verbal Learning (immediate recall). Directionally positive effects were also observed on the Virtual Reality Functional Capacity Assessment Tool (VRFCAT), a measure of real-world functional cognitive capacity. Inidascamine was well-tolerated, with a favorable safety profile consistent with previous studies. Importantly, no evidence of sedation, weight gain, or extrapyramidal symptoms was observed, which are side effects commonly associated with treatments used in people living with schizophrenia. Matt Pando, PhD, Chief Executive Officer and Co-Founder of Recognify Life Sciences, commented: 'Although we are disappointed that the study did not reach statistical significance on the primary efficacy endpoint, we are encouraged by the consistency of improvement signals across multiple cognitive and functional measures as well as replication on specific subsets of the cognitive measures; namely, symbol coding and verbal memory. These findings reinforce our commitment to addressing the significant unmet needs of cognitive impairment associated with numerous mental health and neurodegenerative conditions. Inidascamine continues to exhibit a strong safety profile, and we look forward to analyzing the full data set to better understand the outcome and inform potential next steps for the program.' The randomized, placebo-controlled, double-blind, Phase 2b clinical study enrolled 242 patients across the United States and Europe (NCT05686239). The trial evaluated the efficacy, safety, and tolerability of two doses of inidascamine versus placebo over a six-week treatment period. A comprehensive analysis of remaining secondary and exploratory endpoints, including subgroup analyses, is ongoing to determine whether there are identifiable responder populations or mechanistic insights that may guide future development. Keith Nuechterlein, PhD, Distinguished Professor in the UCLA Department of Psychiatry and Biobehavioral Sciences and co-chair of the MATRICS Neurocognition Committee, commented upon seeing these results: 'Developing treatments for cognitive impairment in schizophrenia is a complex challenge that requires persistence and innovation. I am encouraged by the inidascamine topline results showing consistent directional tendencies for improvement and look forward to seeing the full set of results.' Recognify plans to present additional results from the study at upcoming scientific meetings and will continue to evaluate strategic options for inidascamine based on the totality of data. Srinivas Rao, MD, PhD, Chief Executive Officer and Co-Founder of atai Life Sciences, added: 'CIAS remains a challenging therapeutic area with a significant unmet need. While we believe these results support the continued development of inidascamine by Recognify for CIAS as well as its potential application in other indications, as previously communicated, we intend to allocate atai's resources on our wholly owned pipeline of transformative psychedelic product candidates focused on affective disorders." About Inidascamine Inidascamine, formerly RL-007, is an orally available compound, with unique mechanisms of action for the treatment of cognitive impairment, that modulates cholinergic, glutamatergic and GABA-B receptors, thereby putatively altering the excitatory/inhibitory balance in the brain to produce pro-cognitive effects. It has previously been evaluated in ten clinical studies, including one in the CIAS indication, with over 600 unique participants dosed to date. Clinical studies of inidascamine suggest improvement in cognitive performance, particularly for verbal learning and memory and processing speed. About Schizophrenia and CIASSchizophrenia is a mental health disorder primarily characterized by hallucinations, delusions, and disordered thinking. This condition effects over 21 million people globally and approximately 2.4 million people in the United States, with around 300,000 new cases being diagnosed each year in the US. Cognitive deficits -present in approximately 80% of patients, is a core feature of the illness and contributes significantly to long-term disability and impairments in daily functioning. There are presently no effective pharmaceutical treatments approved for CIAS, representing a high unmet clinical need. About Recognify Life Sciences, Life Sciences is a clinical-stage biotech company on a mission to provide pro-cognitive treatments solutions to mental health and neurodegenerative disorders. The company is a strategic investment of atai Life Sciences. For more information about Recognify, please visit About atai Life Sciencesatai is a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes. atai's pipeline of psychedelic-based therapies includes BPL-003 (mebufotenin benzoate) for treatment-resistant depression (TRD), which is being advanced through a planned strategic combination with Beckley Psytech Limited; VLS-01 (buccal film DMT) also for TRD; and EMP-01 (oral R-MDMA) for social anxiety disorder. All three programs are in Phase 2 clinical development. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD. These programs aim to address the complex nature of mental health providing commercially scalable interventional psychiatry therapies that can integrate seamlessly into healthcare systems. For the latest updates and to learn more about atai's mission, visit or follow the Company on LinkedIn and on X. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the 'Securities Act'), and Section 21E of the Securities Exchange Act of 1934, as amended (the 'Exchange Act'). The words 'believe,' 'may,' 'will,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'expect,' 'initiate,' 'could,' 'would,' 'project,' 'plan,' 'potentially,' 'preliminary,' 'likely,' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. All statements in this press release other than statements of historical fact are forward-looking statements, including, express or implied statements relating to, among other things: statements regarding Recognify Life Science's inidascamine (formerly RL-007) studies, data, or related strategic plans and objectives of management for future operations, capital expenditures and capital allocation. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond our control and which could cause actual results, levels of activity, performance, or achievements to differ materially from those expressed or implied by these forward-looking statements. Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, including, without limitation, the important factors described in the section titled 'Risk Factors' in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission ('SEC'), as such factors may be updated from time to time in atai's other filings with the SEC. atai disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by applicable law. Contact InformationInvestor Contact:IR@ atai Media Contact:PR@
